Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bupropion increases striatal vesicular monoamine transport.

Kristi S Rau1, Elisabeth Birdsall, Jarom E Hanson

  • 1Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.

Neuropharmacology
|July 12, 2005
PubMed
Summary

Bupropion, like methylphenidate, increases vesicular dopamine uptake by affecting vesicular monoamine transporter-2 (VMAT-2) and dopamine transporter (DAT) interactions. However, bupropion does not offer the same long-term neuroprotective benefits against methamphetamine toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methcathinone self-administration decreases dopamine and serotonin transporter function in rats.

Drug and alcohol dependence·2026
Same author

Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotype.

Frontiers in psychiatry·2026
Same author

Differential Effects of Neurotensin NTS1 and NTS2 Receptors on Locomotion.

Brain and behavior·2025
Same author

Cognitive-Enhancing Effects of Acetylcholine Receptor Agonists in Group-Housed Cynomolgus Monkeys Who Drink Ethanol.

The Journal of pharmacology and experimental therapeutics·2023
Same author

Molecular mechanism of biased signaling at the kappa opioid receptor.

Nature communications·2023
Same author

Rate of onset of dopamine transporter inhibitors assessed with intracranial self-stimulation and in vivo dopamine photometry in rats.

Psychopharmacology·2023

Area of Science:

  • Neuropharmacology
  • Neuroscience
  • Dopaminergic system research

Background:

  • The vesicular monoamine transporter-2 (VMAT-2) regulates cytoplasmic dopamine (DA) by sequestering it into synaptic vesicles.
  • Previous studies linked striatal VMAT-2 vesicular DA uptake to dopamine transporter (DAT) inhibition, with methylphenidate (MPD) increasing uptake and causing VMAT-2 redistribution.
  • Understanding how other DAT inhibitors affect VMAT-2 is crucial for elucidating dopaminergic terminal mechanisms.

Purpose of the Study:

  • To investigate whether bupropion, another DAT inhibitor, affects VMAT-2 activity and protein distribution similarly to MPD.
  • To compare the effects of bupropion and MPD on VMAT-2 function and their potential neuroprotective roles against methamphetamine (METH) toxicity.

Main Methods:

  • Administration of bupropion to investigate its effects on vesicular DA uptake and VMAT-2 protein redistribution in striatal preparations.

Related Experiment Videos

  • Pretreatment with dopamine receptor antagonists (D1 and D2) to identify the receptor involvement in bupropion's effects.
  • Assessment of bupropion's acute and long-term effects on VMAT-2 activity and METH-induced dopaminergic toxicity.

    • Main Results:

    • Bupropion rapidly, reversibly, and dose-dependently increased vesicular DA uptake, accompanied by VMAT-2 protein redistribution.
    • Bupropion's effect on VMAT-2 was mediated via D2 receptor antagonism, as eticlopride prevented the uptake increase, while SCH23390 (D1 antagonist) did not.
    • While bupropion acutely reduced METH-induced VMAT-2 activity reduction, it failed to prevent long-term dopaminergic toxicity or VMAT-2 redistribution.

    Conclusions:

    • Bupropion shares mechanistic similarities with MPD in modulating VMAT-2 and DAT interactions within dopaminergic terminals.
    • Bupropion's effects on VMAT-2 are D2 receptor-dependent.
    • Unlike MPD, bupropion does not provide long-term neuroprotection against METH-induced dopaminergic toxicity and VMAT-2 redistribution.